Shares of Myriad Genetics Inc. (NASDAQ:MYGN) traded down 2.9% on Friday . The company traded as low as $29.09 and last traded at $31.14, with a volume of 1,066,984 shares trading hands. The stock had previously closed at $32.07.

Several analysts have commented on the stock. Zacks Investment Research downgraded shares of Myriad Genetics from a “hold” rating to a “sell” rating in a report on Thursday, April 14th. Leerink Swann restated a “market perform” rating and set a $44.00 target price on shares of Myriad Genetics in a report on Wednesday, April 20th. Mizuho restated a “neutral” rating and set a $34.00 target price (down from $42.00) on shares of Myriad Genetics in a report on Wednesday, May 4th. Avondale Partners dropped their target price on shares of Myriad Genetics from $50.00 to $47.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 4th. Finally, Bank of America Corp. restated a “hold” rating and set a $39.00 target price on shares of Myriad Genetics in a report on Wednesday, May 4th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company. Myriad Genetics presently has a consensus rating of “Buy” and an average target price of $42.31.

The firm’s 50-day moving average is $31.09 and its 200-day moving average is $35.25. The stock has a market capitalization of $2.18 billion and a price-to-earnings ratio of 20.93.

Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Tuesday, May 3rd. The company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.03. The firm had revenue of $190.50 million for the quarter, compared to analyst estimates of $185.08 million. Myriad Genetics’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.40 earnings per share. Equities analysts anticipate that Myriad Genetics Inc. will post $1.65 EPS for the current fiscal year.

In other news, insider Alexander Ford sold 18,637 shares of the company’s stock in a transaction that occurred on Tuesday, June 21st. The stock was sold at an average price of $30.87, for a total transaction of $575,324.19. Following the transaction, the insider now directly owns 40,122 shares of the company’s stock, valued at $1,238,566.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Several institutional investors have recently modified their holdings of MYGN. Fiduciary Management Associates LLC purchased a new position in shares of Myriad Genetics during the fourth quarter worth $17,415,000. California Public Employees Retirement System raised its position in shares of Myriad Genetics by 4.6% in the fourth quarter. California Public Employees Retirement System now owns 307,600 shares of the company’s stock worth $13,276,000 after buying an additional 13,400 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Myriad Genetics by 472.0% in the fourth quarter. Ameritas Investment Partners Inc. now owns 30,660 shares of the company’s stock worth $1,322,000 after buying an additional 25,300 shares during the last quarter. Morgan Stanley raised its position in shares of Myriad Genetics by 363.0% in the fourth quarter. Morgan Stanley now owns 614,409 shares of the company’s stock worth $26,517,000 after buying an additional 481,702 shares during the last quarter. Finally, Nationwide Fund Advisors raised its position in shares of Myriad Genetics by 2.0% in the fourth quarter. Nationwide Fund Advisors now owns 45,572 shares of the company’s stock worth $1,967,000 after buying an additional 896 shares during the last quarter.

Myriad Genetics, Inc (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing, or assess a patient’s risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.